LEVOVID 750mg/150ml Infusion

Levofloxacin 750 mg / 150 ml



Levovid®Infusion 750 mg/150 ml, each 150 ml contains : Levofloxacin hemihydrate equivalent to Levofloxacin 750 mg.



Levovid®contains Levofloxacin hemihydrate (equivalent to Levofloxacin) as active ingredient are available in infusion 500 mg/100 ml and 750 mg/150 ml.



Levovid® is indicated for the treatment of adults (≥ 18 years of age) with mild, moderate and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed below :

  • Acute maxillary sinusitis : Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis.
  • Acute bacterial exacerbationof chronic bronchitis : Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae or Moraxella catarrhalis.
  • Community acquired pneumonia : Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Legionella pneumophila or Mycoplasma pneumoniae.
  • Complicated skin and skin structure infections : Methicillin-resistant Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes or Proteus mirabilis.
  • Uncomplicated skin and skin structure infections (mild to moderate including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections) : Staphylococcus aureus or Streptococcus pyogenes.
  • Complicated urinary tract infections (mild to moderate):Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis or Pseudomonas aeruginosa.
  • Acute pyelonephritis (mild to moderate) caused by Escherichia coli.
  • Uncomplicated urinary tract infections (mild to moderate) : Escherichia coli, Klebsiella pneumoniae or Staphylococcus saprophyticus.

Levofloxacin IV is only given to the patients who are unable to use the oral dosage form.



Usual dose in patients with normal renal :

250 – 750 mg once daily for 3 – 14 days depending on the severity of the disease.

Patients with normal renal function :                    

Infection Levofloxacinonce daily
Unit dose Duration
Acute maxillary sinusitis 500 mg 10 – 14 days
Acute bacterial exacerbation of chronic bronchitis 500 mg 7 days
Community acquired pneumonia 500 mg 7 – 14 days
Complicated skin & skin structure infections 750 mg 7 – 14 days
Uncomplicated skin & skin structure infections 500 mg 7 – 10 days
Complicated UTI 250 mg 10 days
Uncomplicated UTI 250 mg 3 days
Acute pyelonephritis 250 mg 10 days

Patients with impaired renal function :

Renal status Levofloxacin once daily
Acute bacterial exacerbation of chronic bronchitis/ Community acquired pneumonia/Acute maxillary sinusitis/Uncomplicated skin & skin structure infections Initial dose Subsequent dose
ClCr from 50 to 80 ml/minute No dosage adjustment required
ClCr from 20 to 49 ml/minute 500 mg 250 mg q 24 h
ClCr from 10 to 19 ml/minute 500 mg 250 mg q 48 h
Hemodialysis 500 mg 250 mg q 48 h
CAPD 500 mg 250 mg q 48 h
Complicated skin & skin structure infections
ClCr from 50 to 80 ml/minute No dosage adjustment required
ClCr from 20 to 49 ml/minute 750 mg 750 mg q 48 h
ClCr from 10 to 19 ml/minute 750 mg 500 mg q 48 h
Hemodialysis 750 mg 500 mg q 48 h
CAPD 750 mg 500 mg q 48 h
Complicated UTI/Acute pyelonephritis
ClCr 20 ml/minute No dosage adjustment required
ClCr from 10 to 19 ml/minute 250 mg 250 mg q 48 h
Uncomplicated UTI No dosage adjustment required

ClCr = Creatinine Clearances

CAPD = Chronic Ambulatory Peritoneal Dialysis

Levofloxacin IV is administered by slow IV infusion. It is usually possible to switch from initial IV treatment to the oral route after a few-days, according to the condition of the patients.

Administration :

  • Levofloxacin IV is ready for use and should only be administered by slow IV infusion. The infusion time for 500 mg (100 ml) and 750 mg (150 ml) should not be less than 60 minutes (1 hour) and 90 minutes (1.5 hours). Protection from light is not necessary during infusion time. Once the vial has been opened (rubber stopper perforated) the solution should be used immediately (within 3 hours) in order to prevent any bacterial contamination.
  • Levofloxacin IV should not be mixed with Heparin or alkaline solution (e.g., Sodium hydrogen carbonate).
  • Levofloxacin IV should be administered alone unless compatibility with other infusion fluids has been demonstrated.



Levofloxacin is contraindicated in patients with a history of hypersensitivity to Levofloxacin, quinolone antimicrobial agents or any other components of this product.



Warnings :

Convulsion and toxic psychoses have been reported in patients receiving quinolones, including Levofloxacin. It may also increased intracranial pressure and CNS stimulation which may lead to tremors, restlessness, anxiety, lightheadedness, confusion, hallucinations, paranoia, depression, nightmare, insomnia and rarely suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving Levofloxacin, this drug should be discontinued.

Precautions :

  • Although Levofloxacin is more soluble than other quinolones, adequate hydration of patients receiving Levofloxacin should be maintained to prevent the formation of a highly concentrated urine.
  • Administered Levofloxacin with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of Levofloxacin may be reduced. In patients with impaired renal function (creatinine clearance ≤ 80 ml/minute), adjustment of the dosage regimen is necessary to avoid the accumulation of Levofloxacin due to decreased clearance.
  • Moderate to severe phototoxicity reactions have been observed in patients exposed to direct sunlight while receiving drugs in this class. Therapy should be discontinued if phototoxicity (e.g., a skin eruption) occurs.
  • As with other quinolones, Levofloxacin should be used with caution in any patient with a known or suspected CNS disorder that may predispose to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold (e.g., certain drug therapy, renal dysfunction).
  • Use in pregnancy and lactation : The safety and efficacy of Levofloxacin in pregnant women and nursing mothers have not been established.
  • Use in children : The safety and efficacy of Levofloxacin in children and adolescents < 18 years have not been established.
  • If during the use of fluoroquinolone patient experiences pain, swelling, tendon and rupture tendon inflammation, then :
    1. Levofloxacin should be discontinued.
    2. Patient should contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug.
    3. Patient should avoid exercise and using the affected area.



Levovid® Infusion 750 mg/150 ml          Box, 1 bottle @ 150 ml                                                      Reg. No. DKL1502342949B1







Manufactured by :


Sidoarjo – Indonesia